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Summary
By studying the loci that contribute to human longevity,
we aim to identify mechanisms that contribute to healthy
aging. To identify such loci, we performed a genome-
wide association study (GWAS) comparing 403 unrelated
nonagenarians from long-living families included in the
Leiden Longevity Study (LLS) and 1670 younger popula-
tion controls. The strongest candidate SNPs from this
GWAS have been analyzed in a meta-analysis of nonage-
narian cases from the Rotterdam Study, Leiden 85-plus
study, and Danish 1905 cohort. Only one of the 62 priori-
tized SNPs from the GWAS analysis (P <1· 10
)4) showed
genome-wide signiﬁcance with survival into old age in
the meta-analysis of 4149 nonagenarian cases and
7582 younger controls [OR = 0.71 (95% CI 0.65–0.77),
P = 3.39 · 10
)17]. This SNP, rs2075650, is located in
TOMM40 at chromosome 19q13.32 close to the apolipo-
protein E (APOE) gene. Although there was only moder-
ate linkage disequilibrium between rs2075650 and the
ApoE e4 deﬁning SNP rs429358, we could not ﬁnd an
APOE-independent effect of rs2075650 on longevity,
either in cross-sectional or in longitudinal analyses. As
expected, rs429358 associated with metabolic pheno-
types in the offspring of the nonagenarian cases from the
LLS and their partners. In addition, we observed a novel
association between this locus and serum levels of IGF-1
in women (P = 0.005). In conclusion, the major locus
determining familial longevity up to high age as detected
by GWAS was marked by rs2075650, which tags the dele-
terious effects of the ApoE e4 allele. No other major lon-
gevity locus was found.
Key words: aging; apolipoprotein E; genetics; genome-
wide association study; human; longevity.
Introduction
Worldwide human populations have shown an increase in mean
life expectancy in the past two centuries (Oeppen & Vaupel,
2002). This is mainly because of environmental factors such as
improved hygiene, nutrition, and health care. The large variation
in healthy lifespan among the elderly has prompted research
into the determinants of aging and lifespan regulation. The
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at 25–30% in twin studies (Gudmundsson et al., 2000; Skytthe
et al., 2003; Hjelmborg et al., 2006). The most prominent
genetic inﬂuence is observed in families in which the capacity to
attain a long lifespan clusters (Perls et al., 2000; Schoenmaker
et al., 2006). Exceptional longevity can be reached with a low
degree of age-related disability (Christensen et al., 2008; Terry
et al., 2008), raising the question whether protective mecha-
nisms against disease exist in long-lived subjects.
In most experimentally modiﬁed animal model systems, sin-
gle-gene mutations in many different genes have major life
extension effects (Fontana et al., 2010; Kenyon, 2010). How-
ever, natural human and animal longevity is presumed to be a
complex trait (Finch & Tanzi, 1997). In humans, both candidate
gene and genome-wide genetic association approaches have
been applied in an attempt to identify longevity loci. The fre-
quency of genetic variants has been typically compared
between nonagenarian cases and young controls, revealing
loci at which genetic variants may contribute to a higher or
lower probability of survival into old age. The initial candidate
gene studies aimed at ﬁnding human longevity genes were
dominated by contradictory results (Christensen et al., 2006).
The more consistent evidence obtained by repeated observa-
tion in independent cohort studies for association with longev-
ity has so far only been observed for three loci, the
apolipoprotein E (APOE) locus (Schachter et al., 1994; Chris-
tensen et al., 2006), the FOXO3A locus (Willcox et al., 2008;
Flachsbart et al., 2009; Pawlikowska et al., 2009; Soerensen
et al., 2010), and the AKT1 locus (Pawlikowska et al., 2009).
Thus, despite the expectation that longevity would be inﬂu-
enced by many genetic variants with small effect sizes, the
effect of variants has consistently been shown in only three
genes.
Hypothesis-free genome-wide approaches have also been
undertaken. Genome-wide linkage scans reported evidence for
linkage with longevity on chromosome 4q25 (Puca et al., 2001),
3p24-22, 9q31-34, and 12q24 (Boyden & Kunkel, 2010). How-
ever, the evidence for these loci is still very weak as the results,
obtained in centenarians and their families, could not be repli-
cated in nonagenarian sibling pairs (Beekman et al., 2006) or
have yet to be tested in other studies. A meta GWAS of survival
to 90 years or older in 1836 cases and 1955 controls did not ﬁnd
any signiﬁcant genome-wide associations (Newman et al.,
2010). Thus far, hypothesis-free approaches have not identiﬁed
any loci involved in longevity.
In a few studies, such as the Ashkenazi Jewish Centenarian
Study and the Leiden Longevity Study (LLS), different genera-
tions of long-lived families are being investigated for parameters
and pathways contributing to the longevity phenotype (Atzmon
et al., 2004; Schoenmaker et al., 2006). The survival beneﬁt of
the LLS families is marked by a 30% decreased mortality risk in
the survival analysis of three generations, i.e., the parents of the
probands in this study (nonagenarian sibling pairs), their unse-
lected additional siblings, and their offspring (Schoenmaker
et al., 2006). As compared to their partners, the offspring of
nonagenarians siblings have a lower prevalence of type 2 diabe-
tes, myocardial infarction and hypertension (Westendorp et al.,
2009), a beneﬁcial glucose, lipid, and thyroid metabolism, and a
preservation of insulin sensitivity with age (Rozing et al., 2009,
2010a,b; Vaarhorst et al., 2011; Wijsman et al., 2011). Hence,
in middle age, these families display beneﬁcial metabolic
proﬁles.
Because the longevity phenotype is inherited in the LLS fami-
lies, they offer a route to identify genetic variants that inﬂuence
human longevity. Previously, we tested whether the absence of
GWAS-identiﬁed alleles promoting common diseases might
explain their familial longevity (Beekman et al., 2010). Longevity
was not easily explained by the absence of disease-susceptibility
alleles. More likely therefore, the genome of the long-lived har-
bors longevity-promoting alleles. To identify such loci, we per-
formed a GWAS comparing nonagenarian siblings from the LLS
and younger population controls. We subsequently investigated
emerging candidate SNPs in nonagenarian cases from the Rot-
terdam Study, the Leiden 85-plus study, and the Danish 1905
cohort.
Results
GWAS
A GWAS was performed in nonagenarian participants from the
LLS and middle-aged controls from the Rotterdam Study (RS).
Genotype data for 516,721 SNPs that passed quality control
thresholds were analyzed in a comparison of 403 unrelated
nonagenarians (94 years on average) and 1670 controls
(58 years on average). A ﬂow chart of the consecutive analysis
steps is depicted in Fig. 1, and a description of the population
samples investigated in the GWAS and subsequent replication
studies is given in Table 1. Results of the association analysis of
stage 1 are depicted in Fig. S1. None of the SNPs reached
genome-wide signiﬁcance (P <5· 10
)8).
Replication studies
We prioritized the SNPs that had the most signiﬁcant association
with survival into old age according to the analysis of stage 1
(P <1· 10
)4, Table S1). For 58 of the 62 selected SNPs, suc-
cessful genotyping was obtained in the replication cohorts. In
stage 2, these 58 SNPs were tested for association comparing
960 RS replication cases (mean age of 93 years), 1208 Leiden
85-plus replication cases (mean age of 92 years), and 1578 Dan-
ish replication cases (mean age of 93 years) with appropriate
middle-aged population controls (Table 1). Meta-analysis for
the 58 SNPs, comprising a total of 4149 nonagenarian cases and
7582 younger controls (from the LLS GWAS, RS replication,
Leiden 85-plus replication, and Danish replication studies), was
performed.
Rs2075650 on chromosome 19 was the only SNP that was
associated with survival into old age at the genome-wide signi-
ﬁcance level (P = 3.39 · 10
)17) (Table S2A). The minor allele
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687was underrepresented among the older cases as compared to
middle-aged controls, hence associated with the decreased
probability of carriers surviving into old age corresponding to an
odds ratio (OR) below unity [OR = 0.71 (95% CI 0.65-0.77)].
This effect is observed in both sexes (Table S2B, C). The remain-
ing 57 SNPs did not show genome-wide signiﬁcant effects on
longevity either in men or women (Table S2B for men and S2C
for women). The association of rs2075650 with survival did
show some heterogeneity across the four studies (P = 0.0495),
which is mainly because of the RS.
rs2075650 and the APOE e2⁄e3⁄e4 polymorphism
Rs2075650 is located in the TOMM40 gene, next to the APOE
gene (Fig. S2). APOE was previously associated with longevity
(Schachter et al., 1994; Christensen et al., 2006). The ApoE pro-
tein has three isoforms (ApoE e2, ApoE e3, and ApoE e4) which
are deﬁned by two SNPs, rs7412 (Arg136Cys; e2) and rs429358
(Cys112Arg; e4). A meta-analysis of rs7412 and rs429358, in
the LLS GWAS study, the Leiden 85-plus replication study, and
the Danish replication study samples (3189 cases and 5757
controls), showed a signiﬁcant association of rs429358 with
longevity [OR = 0.62 (95% CI 0.56–0.68), P = 1.33 · 10
)23],
which was comparable to rs2075650 [OR = 0.67 (95% CI 0.61–
0.74), P = 9.15 · 10
)17]. Rs7412 also showed an association
with longevity, with a higher prevalence of the minor allele in
nonagenarians [OR = 1.31 (95% CI 1.17–1.46), P = 1.35 ·
10
)6].
We observed only moderate linkage disequilibrium (LD)
between rs2075650 and rs429358 (r
2 = 0.553) and low LD
between rs2075650 and rs7412 (r
2 = 0.014) when analyzing all
samples with genotype data of rs2075650, rs429358, and
rs7412 (n = 8946). Nevertheless, in a conditional analysis with
rs429358 and rs7412 (Model 1, described in the Experimental
procedures section), rs2075650 was no longer associated with
longevity [OR = 0.93 (95% CI 0.81–1.07), P = 0.337]. The OR
increased from 0.67 to 0.93, i.e., the deleterious effect of
rs2075650 on longevity diminishes and is statistically non-signif-
icant. However, the deleterious effect of rs429358 [OR = 0.64
(95% CI 0.56–0.74), P = 2.68 · 10
)9] and the protective effect
of rs7412 [OR = 1.20 (95% CI 1.07–1.36), P = 0.002] on lon-
gevity remained signiﬁcant.
GWAS
Replication
Nr of SNPs Study sample Analysis
Meta-analysis:
LLS GWAS
RS replication study
85-plus replication study
Danish replication study
Total:
4149 85+ cases
7582 younger controls
P
meta< 5 × 10
–8
58
Cochran-armitage trend test:
P
trend< 1 × 10
–4
LLS GWAS:
403 90+ cases
1670 younger controls
517K
Prospective analysis:
All cause mortality
1
RS replication study:
960 90+ cases
1825 younger controls
85-plus replication study:
1208 85+ cases
2090 younger controls
Danish replication study: 
1578 92+ cases
1997 younger controls
Leiden Longevity Study: 
944 90+ cases
Leiden 85-plus study: 
976 85+ cases
Danish 1905 cohort: 
1578 92+ cases
Follow-up
Fig. 1 Flow chart of experimental work.
Table 1 Characteristics of the genotyped samples used for analysis
Study SNPs Samples Number Mean age Age range Men ⁄women
LLS GWAS 517K Cases 403 94 89–102 137 ⁄ 266
517K Controls 1670 58 55–59 745 ⁄ 925
RS replication study 58 Cases 960 94 90–106 217 ⁄ 743
58 Controls 1825 62 60–65 805 ⁄ 1020
Leiden 85-plus replication study 58 Cases 1208 92 85–109 372 ⁄ 836
58 Controls 2090 35 15–70 743 ⁄ 1347
Danish replication study 58 Cases 1578 93 92–93 430 ⁄ 1148
58 Controls 1997 57 46–68 900 ⁄ 1097
LLS, Leiden Longevity Study; RS, Rotterdam Study; GWAS, genome-wide association study.
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688To determine whether there was an APOE-independent
effect of rs2075650 on survival after 90 years, prospective
analysis of rs2075650, adjusted for rs429358 and rs7412, was
performed. This analysis showed that carriers of the minor
allele of rs2075650 displayed no increased mortality, i.e., a sig-
niﬁcant hazard ratio (HR) above 1, after 90 years of age inde-
pendently of APOE in two of the three cohorts analyzed [LLS,
HR = 0.99 (95% CI 0.78–1.25), P = 0.914; Leiden 85-plus
study, HR = 1.06 (95% CI 0.89–1.27), P = 0.521; Danish 1905
cohort, HR = 1.21 (95% CI 1.01–1.44), P = 0.036) (Table S3A,
Fig. S3).
Overall, our results suggest that the association of rs2075650
with longevity is most likely a reﬂection of the effects of
rs429358, caused by the moderate LD between the loci.
Association of rs429358 (e4) and rs2075650 with
serum parameters
As previous studies showed that rs429358 was associated with
several metabolic phenotypes (Boerwinkle & Utermann, 1988;
Topic et al., 2008; Hubacek et al., 2010), association of this
SNP with relevant serum parameters was determined in the off-
spring of the elderly LLS cases and their partners (n = 2324,
Model 2 described in the Experimental procedures section). We
replicated the previously reported associations of rs429358
with plasma levels of ApoE (P = 7.42 · 10
)28), total cholesterol
(P = 0.001), LDL cholesterol (P = 4.91 · 10
)5), HDL cholesterol
(P = 0.062), and high sensitivity C-reactive protein (hsCRP)
(P = 0.028) and with HDL (P = 0.061) and LDL particle size
(P = 0.062) (Table 2). In addition, we detected a minor effect
on IGF-1 (P = 0.025) and IGFBP3 levels (P = 0.042) (Table 2).
The effect on IGF-1 seems to be female-speciﬁc (P = 0.005 and
P = 0.748, in women and men, respectively) and is still signiﬁ-
cant after correction for multiple testing. We observed no
APOE-independent effect of rs2075650 on these traits, except
for an increase of 0.18 mmol L
)1 total cholesterol (P = 0.017)
and 0.14 mmol L
)1 LDL cholesterol (P = 0.014) with each
minor allele of rs2075650 (using Model 3 described in the
Experimental procedures section).
No signiﬁcant effects of rs429358 were observed on glucose
(P = 0.388), insulin (P = 0.123), triglyceride (P = 0.203), and
fT3 (P = 0.141) levels (Table 3); the phenotypes that have previ-
ously been associated, in middle age, with familial longevity in
the LLS families (Rozing et al., 2009, 2010a,b; Vaarhorst et al.,
2011; Wijsman et al., 2011).
Analysis of Alzheimer’s disease SNPs
Rs2075650 has consistently been associated with an increased
risk of Alzheimer’s disease in several independent GWAS studies
(Harold et al., 2009; Lambert et al., 2009; Seshadri et al.,
2010). Therefore, we studied the effect of SNPs present in the
AlzGene database [http://www.alzgene.org/, (Bertram et al.,
2007)], on survival into old age in the LLS GWAS. Apart from
rs2075650, none of the 751 measured Alzheimer’s disease SNPs
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689showed a signiﬁcant association after adjustment for multiple
testing (Table S4).
Analysis of FOXO3A and AKT1 SNPs
Apart from APOE, two other genes have shown consistent evi-
dence for association with longevity, FOXO3A (Willcox et al.,
2008; Flachsbart et al., 2009; Pawlikowska et al., 2009; Soeren-
sen et al., 2010) and AKT1 (Pawlikowska et al., 2009). For the
longevity-promoting FOXO3A SNPs previously reported with
centenarian longevity, we observed no association with survival
into old age in our nonagenarians (Table S5). For AKT1, one of
the two measured SNPs, rs2498804, showed a signiﬁcant asso-
ciation with survival into old age [OR = 0.75 (95% CI 0.63–
0.89), P = 0.001] (Table S5).
Discussion
To identify common SNPs contributing to longevity, GWAS
analysis of 403 nonagenarian cases and 1670 population con-
trols was performed. Of the 62 top associating SNPs, 58 were
tested in a meta-analysis of 4149 nonagenarian cases and
7582 younger controls and we identiﬁed one SNP, rs2075650,
that associated signiﬁcantly with survival into old age
(P = 3.39 · 10
)17). Carriers of the minor allele had a 29%
decreased probability of reaching 90 years on average.
Although cases and controls originate from different genera-
tions, we concluded that there was no substructure to an
extent that would affect the observations.
Rs2075650 is located in the TOMM40 gene at chromosome
19q13.32 close to and centromeric of the APOE gene (Fig. S2),
which has shown consistent evidence for association with lon-
gevity (Schachter et al., 1994; Christensen et al., 2006). The
ApoE protein has three isoforms (ApoE e2, ApoE e3, and ApoE
e4) that are deﬁned by two SNPs, rs7412 (Arg136Cys; e2) and
rs429358 (Cys112Arg; e4). ApoE e4 carriers have an increased
risk of cardiovascular disease and Alzheimer’s disease, while
ApoE e2carriers areprotected fromthese diseases (Corderet al.,
1993; Eichner et al., 1993; Christensen et al., 2006). Although
we detected only moderate LD (r
2 = 0.553) between rs2075650
and the ApoE e4-deﬁning SNP rs429358, we could not detect a
signiﬁcant effect of rs2075650 on longevity independent of
rs429358. Several prospective studies, including one with the
Danish 1905 cohort (Jacobsen et al., 2010), reported increased
mortality for ApoE e4 carriers, even though there is still much
debate about APOE being a ‘frailty gene’ or a ‘longevity gene’
(Gerdes et al., 2000; Christensen et al., 2006; Ewbank, 2007;
Jacobsen et al., 2010). The prospective data in the LLS and Lei-
den 85-plus study support the ‘frailty gene’ hypothesis, as
rs429358 affects mortality after 85 years and continues the
effect after 90 years [HR = 1.08 (95% CI 1.03–1.13), P = 0.001
and HR = 1.08 (95% CI 1.03–1.12), P = 0.001, respectively]
(Table S3B, Fig. S4). In these prospective studies, carriers of the
minor allele of rs2075650 showed no increased mortality inde-
pendent of rs429358, which indicates that the association of
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690rs2075650 with longevity is most likely due to variation in the
APOE gene. Although GWAS studies have reported signiﬁcant
associations between rs2075650 and Alzheimer’s disease, brain
imaging, total cholesterol, and CRP plasma levels (Reiner et al.,
2008; Aulchenko et al., 2009; Seshadri et al., 2010; Shen et al.,
2010), no analyses were performed to determine whether these
associations are APOE independent. We observed no APOE-
independent effect on the phenotypes investigated in the LLS
offspring and partners except for totalandLDL cholesterol.
Previously, rs429358 had been associated with several meta-
bolic phenotypes, such as ApoE, total cholesterol, HDL choles-
terol, LDL cholesterol, and hsCRP levels, as well as HDL and LDL
particle size (Boerwinkle & Utermann, 1988; Topic et al., 2008;
Hubacek et al., 2010) and, here, we have conﬁrmed these ﬁnd-
ings using serum measurements of the offspring and partners
from the LLS. Because the insulin⁄IGF-1 signaling (ISS) pathway
has a lifespan regulating effect in several model organisms (Fon-
tana et al., 2010; Kenyon, 2010) and humans (Suh et al., 2008),
we also investigated the effect of rs429358 on serum levels of
IGF-1 and IGFBP3, which both play a role in this pathway. Both
proteins are involved in the etiology of several age-related dis-
eases. However, up till now, it is not clear whether higher or
lower serum levels are beneﬁcial for longevity. Low IGF-1 serum
levels associate to a decreased risk of cancer, but an increased
risk of cardiovascular disease and neurodegenerative disease
(Juul, 2003). Previously, we showed in the Leiden 85-Plus Study
cohort that genetic variants known to associate to lower IIS
activity and IGF-1 serum levels at younger age associated with
better survival at ages above 85 years (van Heemst et al., 2005).
However, the effect of these genetic variants on IGF-1 serum
levels was not tested in the Leiden 85-Plus Study cohort. In addi-
tion, we showed previously that neither IGF-1 and IGFBP3 levels
nor their ratio differed between partners and offspring from the
LLS (Rozing et al., 2009), which indicates that IGF-1 serum levels
are, in middle age, not a marker for longevity, whereas a
decreased risk of metabolic diseases was evident at that age in
long-lived families (Westendorp et al., 2009). In the current
study, we found that the minor allele of rs429358 associates
with lower IGF-1 levels in middle-aged women, which to our
knowledge has not previously been reported. Like low IGF-1 lev-
els, ApoE e4 was previously associated with an increased risk of
developing cardiovascular disease and neurodegenerative dis-
ease (Corder et al., 1993; Eichner et al., 1993; Christensen
et al., 2006). Thus, the mechanism behind the increased risk of
female ApoE e4 carriers of developing cardiovascular and⁄or
neurodegenerative diseases might involve serum levels of IGF-1
or other aspects of IIS activity reﬂected by these levels. Apart
from lipid metabolism, the parameters determining the longev-
ity phenotype in middle age in the LLS, such as glucose metabo-
lism, insulin sensitivity, and thyroid hormone metabolism
(Rozing et al., 2009, 2010a,b; Vaarhorst et al., 2011; Wijsman
et al., 2011), were not inﬂuenced by the presence of the minor
allele of rs429358. This indicates that it is likely that other loci
could explain the differences in these phenotypes between LLS
offspring and partners.
The strength of this study is that, by using a GWAS, we were
able to replicate the previously reported association of the APOE
locus with longevity (Schachter et al., 1994; Christensen et al.,
2006) as the major locus. This was not observed in the previously
published meta genome-wide association study of Newman
et al. (Newman et al., 2010), possibly because of differences in
the study design and population control selection between the
studies. While Newman et al. used nonagenarian cases in a pop-
ulation-based design, we made use of a family-based design in
which the families are genetically enriched for longevity. In addi-
tion, Newman et al. used population controls from the same
cohort which had died before the age of 80. Between 60 and
80 years however, there might already have been a selection on
survival, decreasing the frequency of ApoE e4 carriers in the con-
trol group. In contrast, we made comparisons to a younger pop-
ulation group (55–60 years) from a different cohort (RS).
As we previously reported that long-lived individuals carry the
same number of disease risk alleles for cardiovascular disease,
cancer, and type 2 diabetes as young controls (Beekman et al.,
2010), we expected to primarily ﬁnd longevity-promoting
alleles. However, although most of the 58 prioritized SNPs
(n = 43) from the LLS GWAS showed a longevity-promoting
effect ranging from 36 to 168%, none of them could be repli-
cated in additional study populations of nonagenarian single-
tons. The only replicated locus is APOE, which is a mortality
locus that has previously been reported to be the major locus
responsible for Alzheimer’s disease (Harold et al., 2009;
Lambert et al., 2009; Seshadri et al., 2010), a well-known age-
related disease. Nevertheless, none of the other Alzheimer’s
disease loci showed an association with survival to 90 years,
which indicates that the remaining genetic variation in longevity
in the LLS could not be explained by the genetic variation which
contributes to Alzheimer’s disease. In addition to APOE, we also
observed evidence for association at the previously reported
AKT1 locus (Pawlikowska et al., 2009) with survival into old age
in the LLS GWAS, although the effect of this SNP is relatively
small (25% decreased probability of becoming 90 years) com-
pared to the effect of rs429358 (51%). The previously reported
longevity-promoting effect of the FOXO3A locus could not be
replicated in this study. This is probably due to the relatively low
number of centenarians in the LLS GWAS case group, in which
the effect of SNPs in FOXO3A on longevity seems to be most
prominent. The still unexplained genetic variation in longevity
might be attributable to rare variants or variants with small
effects, which has previously been reported for other complex
traits, such as Alzheimer’s disease. These loci could not be iden-
tiﬁed in this study because of the relatively small number of
cases in the LLS GWAS, the heterogeneity of factors inﬂuencing
lifespan within populations, and the difference in the design of
the studies used for replication. One way to identify variants
with small effects would be to increase the initial sample size of
the GWAS study and perform replication in other studies of
nonagenarians. Given the higher heritability of longevity at older
ages (Tan et al., 2004), one may also limit the study population
to centenarians or supercentenarians. In addition to common
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691variants with small effects, rare variants with large effects might
play a role in longevity. By whole-genome⁄exome sequencing
of long-lived subjects and their families, rare variants can be
identiﬁed and associated with human longevity.
In conclusion, we have shown that the deleterious effect of
the ApoE e4 allele, tagged by rs2075650, is the single major hit
in our GWAS study for longevity, indicating that no other major
longevity locus was present among these nonagenarians. We
conﬁrmed the previously reported associations of the ApoE e4
allele with lipid metabolism parameters and report an additional
effect on IGF-1 signaling in women. To identify genetic variants
with smaller and protective effects on human lifespan, a meta-
GWAS for longevity with a larger sample size is merited.
Experimental procedures
Study populations
Leiden longevity study
For the LLS, long-lived siblings of European descent were
recruited together with their offspring and the partners of the
offspring. Families were included if at least two long-lived sib-
lings were alive and fulﬁlled the age criterion of 89 years or
older for men and 91 years or older for women, representing
<0.5% of the Dutch population in 2001 (Schoenmaker et al.,
2006). In total, 944 long-lived proband siblings were included
with a mean age of 94 years (range 89–104), 1671 offspring
(61 years, 39–81), and 744 partners (60 years, 36–79). DNA
from the LLS was extracted from samples at baseline using con-
ventional methods (Beekman et al., 2006). For the GWAS, 403
unrelated LLS siblings (one sibling from each sibling pair) were
included (LLS GWAS cases).
Rotterdam study
The Rotterdam Study (RS) is a prospective population-based
study of people aged 55 years and older, which was designed to
study neurological, cardiovascular, locomotor, and ophthalmo-
logical diseases (Teichert et al., 2009). The study consists of
7983 participants from the baseline cohort (RS-I) and 3011 par-
ticipants from an independent extended cohort formed in 1999
(RS-II) from which DNA was isolated between 1990 and 1993
(RS-I) or between 2000 and 2001 (RS-II). For the GWAS, 1731
participants from the combined cohort who were below
60 years of age and for whom GWAS data were available were
included as controls (RS GWAS controls). For the replication
study, 960 cases above 90 years at time of recruitment (RS repli-
cation cases) and 1825 controls between 60 and 65 years at
baseline (RS replication controls) from the combined cohorts, for
whom GWAS data were also available, were included.
Leiden 85-plus study
In the Leiden 85-plus study, two prospective population-based
cohorts were recruited from inhabitants of Leiden (Weverling-
Rijnsburger et al., 1997; der Wiel et al., 2002). Between 1987
and 1989, 673 subjects aged 85 years and older were enrolled
in a prospective study (Cohort 1). Between 1997 and 1999, 563
subjects were enrolled in the month of their 85th birthday with
follow-up (Cohort 2). Subjects were visited at their home, and
there were no exclusion criteria related to health. DNA was
available from the combined cohorts consisting of 1208 subjects
aged 85 years and older (Leiden 85-plus replication cases).
Netherlands twin registry
From the Netherlands Twin Registry (NTR), 2090 unrelated par-
ticipants of European descent for whom DNA was available
were selected as control samples (Boomsma et al., 2008) (Lei-
den 85-plus replication controls). The substructure in the NTR
has been reported before (Sullivan et al., 2009), and in this
study, we included samples aged between 15 and 70 years at
the time of blood sampling, without known family relations (i.e.,
those without any substructure).
Danish 1905 cohort
The participants in this study are from the Danish 1905 birth
cohort recruited in 1998 (Nybo et al., 2003) when they were
aged 92–93 years. From this cohort, 3,600 subjects were still
alive, of whom 2262 participated in the study. Participants were
subjected to a home-based interview on health and lifestyle
parameters, physical and cognitive function tests, and the col-
lection of biological material. The current genetic study com-
prises a total of 1578 of these individuals (Danish replication
cases). Survival was followed up until January 2010. Ninety-nine
percent (1561 subjects) of subjects died in the 12 years of fol-
low-up. Control samples were 1997 twins (one twin for each
pair) between 46 and 68 years of age collected from all over
Denmark (Danish replication controls).
The cases in all three replication cohorts originate from popu-
lation-based cohort studies from a genetic background similar
to the LLS (Heath et al., 2008). All the participants in these stud-
ies have signed an informed consent.
Genotyping
Genome-wide association study (GWAS)
Leiden Longevity Study GWAS cases were genotyped using Illu-
mina Inﬁnium HD Human660W-Quad BeadChips (Illumina, San
Diego, CA, USA). The RS-I and RS-II cohorts were genotyped
using Illumina Inﬁnium II HumanHap 550K Beadchips and Illu-
mina Inﬁnium II HumanHap550-Duo BeadChips (Illumina),
respectively (Teichert et al., 2009).
For the GWAS, we selected 551 606 SNPs for analysis because
these were genotyped in both the LLS GWAS cases and (some
of) the RS GWAS controls. Of these 551 606 SNPs, 34 885 SNPs
were excluded on the basis of the following criteria: SNP call rate
<0.95 or MAF <0.01 in RS GWAS controls or LLS GWAS cases
(n = 8908 and n = 24 586, respectively), and PHWE <1 0
)4 in RS
GWAS controls (n = 1355). In addition, SNPs with a between-
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692chip effect in the RS GWAS controls were removed using a
genotype trend test comparing the RS GWAS controls from RS-I
with RS-II (n = 36), leaving 516,721 SNPs for statistical analysis.
The Illumina clusterplots of the SNPs with P < 1 · 10
)4 (n = 71)
were visually inspected to conﬁrm high-quality genotyping, and
9 SNPs were excluded on the basis of bad clustering in the LLS
GWAS cases or RS GWAS controls.
Genotype data were used to conﬁrm gender and family rela-
tionships. Two RS GWAS control samples were excluded
because of abnormalities in the sex chromosome (both samples
had Triple X Syndrome). Latent clustering of genotypes because
of population substructure was assessed by pairwise identity-by-
state (IBS) distance using Graphical Relationship Representation
(GRR) [http://bioinformatics.well.ox.ac.uk/GRR, (Abecasis et al.,
2001)]. LLS GWAS cases showed no relationship errors. From
the RS GWAS controls, 59 samples were excluded because of
high IBS. In total, 403 LLS GWAS cases and 1670 RS GWAS con-
trol samples with a sample call rate >0.95 were analyzed.
Because cases and controls originate from different generations,
we investigated whether substructure in these cohorts could
have inﬂuenced the observed associations. IBS estimates for all
pairs of subjects in the data set were computed on a randomly
selected set of 10% of the SNPs that passed quality control
thresholds, using the –genome, –cluster, and –mds-plot 4 com-
mands in PLINK [http://pngu.mgh.harvard.edu/purcell/plink,
(Purcell et al., 2007)]. The ﬁrst two resulting principal compo-
nents (C1 and C2) were plotted against each other, which gives
a representation of the data in two dimensions. In the resulting
scatter plot, each point represents an individual (green = LLS
GWAS case and blue = RS GWAS control) (Fig. S5). If there had
been substructure, one would see multiple clusters in one plot.
However, because all our samples seem to be in one cluster, we
concluded that there was no substructure to an extent that
would affect the observations.
Replication studies
For the RS replication study, we used the existing GWAS data in
the Rotterdam Study after the quality control screening
described by Teichert et al. (Teichert et al., 2009). For the Leiden
85-plus and Danish replication studies, genotyping was per-
formed using the Sequenom MassARRAY iPLEX Gold and Taq-
Man SNP Genotyping assays. Of the 62 prioritized SNPs, 58
could be designed for replication studies using Sequenom, of
which 56 were successfully genotyped in >95% of the samples
displayed in Table 1. The average genotype call rate for SNPs
genotyped with Sequenom was 98.40%, and the average con-
cordance rate with GWAS data among the LLS GWAS cases was
99.97%. For 2 of the 6 SNPs that could not be genotyped
with Sequenom, rs2075650 and rs642990, pre-designed
TaqMan SNP genotyping assays (C___3084828_20 and
C___2206314_20, respectively) were used for genotyping, fol-
lowing the manufacturer’s instructions. The average genotype
call rate for the SNPs genotyped with TaqMan was 99.04%, and
the average concordance rate with GWAS data among the LLS
GWAS cases was 100%.
APOE e2⁄e3⁄e4 polymorphism
The APOE e2⁄e3⁄e4 deﬁning SNPs, rs429358 (Cys112Arg; e4)
and rs7412 (Arg136Cys; e2), were genotyped in the LLS GWAS
cases, Leiden 85-plus replication study, and Danish replication
study controls using pre-designed TaqMan SNP genotyping
assays (C___3084793_20 and C____904973_10, respectively).
For the RS GWAS controls and Danish replication study cases,
previously measured data were used (Slooter et al., 1998; Jac-
obsen et al., 2010).
Measurement of serum parameters
All standard serum measurements were performed using fully
automated equipment.
Glucose, total cholesterol, high-density lipoprotein choles-
terol (HDL-C), and triglyceride levels were measured using the
Hitachi Modular P 800 (Roche, Almere, the Netherlands) (Ro-
zing et al., 2009). Low-density lipoprotein cholesterol (LDL-C)
was calculated using the Friedewald formula (Friedewald et al.,
1972).
LDL and HDL particle sizes were measured using proton NMR
spectroscopy (LipoScience Inc, Raleigh, NY, USA) (Heijmans
et al., 2006).
Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-
binding protein 3 (IGFBP3), and insulin levels were measured
using the Immulite 2500 (DPC, Los Angeles, CA, USA) (Rozing
et al., 2009).
Free triiodothyronine (fT3) was measured using the Modular
E170, and hsCRP was measured using Cobas Integra 800 (both
from Roche) (Rozing et al., 2010b).
The level of ApoE was determined in serum samples using a
human ApoE-speciﬁc sandwich ELISA (van Vlijmen et al., 1994;
Mooijaart et al., 2006).
Statistical analysis
GWAS and replication studies
For the association analysis of the GWAS data, we applied a
Cochran-Armitage trend test (Cochran, 1954; Armitage, 1955).
For X-linked SNPs, the genotypes of the men were considered as
homozygous genotypes. SNPs with a P-value <1 · 10
)4 (n =6 2 )
were selected for replication. Odds ratios were estimated and
the corresponding 95% conﬁdence intervals were computed.
For meta-analyses, a ﬁxed effect approach was used. Scores and
their variances were computed within each study and combined
across the four studies to obtain a single meta-statistic. P-values
below 5 · 10
)8 were considered as genome-wide signiﬁcant
(Pe’er et al., 2008). The between-study variance was calculated
to determine heterogeneity across the four studies. All these
analysis were performed using Bioconductor R [http://www.bio-
conductor.org, (Gentleman et al., 2004)].
The quantile–quantile plot (Fig. S6), constructed using Biocon-
ductor R [http://www.bioconductor.org, (Gentleman et al.,
2004)], showed that the P-value distribution of stage 1 con-
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693formed to a null distribution at all but the extreme tail. The
genomic inﬂation factor (k), which measures over-dispersion of
test statistics from association tests indicating population stratiﬁ-
cation, was 1.027 and we therefore decided not to adjust for
population stratiﬁcation.
Linkage disequilibrium between rs2075650 and the APOE
e2⁄e3⁄e4 polymorphism
Pairwise linkage disequilibrium (LD) between rs2075650 and the
APOE e2⁄e3⁄e4 polymorphism determining SNPs rs7412 and
rs429358 was calculated in 8946 individuals using the –ld com-
mand in PLINK (http://pngu.mgh.harvard.edu/purcell/plink, (Pur-
cell et al., 2007)).
APOE-independent association of rs2075650 with longevity
To determine whether the association of rs2075650 with lon-
gevity was independent of the APOE e2⁄e3⁄e4 polymorphism, a
logistic regression model with adjustment for rs429358, rs7412,
and an interaction term for e2⁄e3 with e3⁄e4 was tested (Ronald
et al., 2009):
Logit (Pstatus =1 )=b0+b1*rs2075650 + b2*rs429358 +
b3*rs7412 + b4*(rs429358*rs7412)+b5*Study (Model 1)
Status was coded as 0 (control) or 1 (long-lived case), Study
was coded as 0 (LLS GWAS), 1 (Leiden 85-plus replication
study), or 2 (Danish replication study), and the genotypes
of rs2075650, rs429358, and rs7412 were coded as 0 (homozy-
gous for the common allele), 1 (heterozygous), or 2 (homozy-
gous for the rare allele). STATA⁄SE 11.1 (StataCorp LP, College
Station, TX, USA) was used for this analysis.
Prospective analysis
Prospective analysis of rs2075650 and rs429358 was performed
with 944 nonagenarian siblings from the LLS, 976 octogenarians
and nonagenarians from the Leiden 85-plus study, and 1578
nonagenarians from the Danish 1905 cohort.
After a mean follow-up time of 5.7 years (LLS), 14.8 years
(Leiden 85-plus study), and 11.4 years (Danish 1905 cohort),
73.2% (n = 691) (LLS), 84.8% (n = 828) (Leiden 85-plus study),
and 98.9% (n = 1561) (Danish 1905 cohort) of the individuals
had died.
Mortality analyses were performed with STATA⁄SE 11.1
(StataCorp LP) using a sex-adjusted, left-truncated Cox propor-
tional hazards model to adjust for late entry into the data set
according to age.
Association of rs429358 (e4) and rs2075650 with serum
parameters
To determine the association of rs429358 and the APOE-inde-
pendent association of rs2075650 with serum parameters in the
offspring and their partners from the LLS, the following regres-
sion models were tested:
Serum parameter = b0+b1*Age + b2*Sex + b3*(Age*Sex) +
b4*Group + b5*rs429358 (Model 2)
Serum parameter = b0+b1*Age + b2*Sex + b3*(Age*Sex)
+ b4*Group + b5*rs2075650 + b6*rs429358 + b7*rs7412 +
b8*(rs429358*rs7412) (Model 3)
Age was coded in years. Sex was coded as 1 (male) or 2
(female), Group was coded as 0 (partner) or 1 (offspring). Robust
standard errors were used to account for sibship relations. STA-
TA⁄SE 11.1 (StataCorp LP) was used for these analyses.
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Supporting Information
Additional supporting information may be found in the online
version of this article:
Fig. S1 Manhattan plot presenting the –log10P from the Coch-
ran-Armitage trend test for the 516,721 SNPs that passed the
quality control thresholds in the LLS GWAS.
Fig. S2 Genomic region surrounding rs2075650 (obtained from
the UCSC genome browser (http://genome.ucsc.edu/). The
physical distances between rs2075650 and rs429358 and
between rs2075650 and rs7412 are 16.32 kb and 16.46 kb,
respectively.
Fig. S3 Kaplan-Meier curves showing the survival rate over years
to follow-up of ApoE e3e3 carriers with zero (solid line) or one
(large dashed line) minor allele(s) of rs2075650 in the LLS, Lei-
den 85-plus study and Danish 1905 cohort.
Fig. S4 Kaplan-Meier curves showing the survival rate over years
to follow-up of carriers of zero (solid line), one (large dashed
line), or two (small dashed line) e4 allele(s) of rs429358 in the
LLS and Leiden 85-plus study.
Fig. S5 C1 values plotted against the C2 values, both resulting
from the multidimensional scaling analysis, of the 403 LLS
GWAS cases (green) and the 1670 RS GWAS controls (blue).
Fig. S6 Quantile–quantile plot of expected vs. observed chi-s-
quare values for the test statistic from the Cochran-Armitage
trend test for 516,721 SNPs that passed the quality control
thresholds in the LLS GWAS. The slope of the dashed line repre-
sents the genomic inﬂation factor (k = 1.027). The shaded
region represents the 95% conﬁdence band.
Table S1 SNPs (n = 62) selected for replication analysis, associ-
ating at P <1· 10
)4 with survival into old age in the analysis of
the LLS GWAS.
Table S2 (A) Results of the association analysis with survival into
old age of the 58 prioritized SNPs from the LLS GWAS in the RS
replication study, Leiden 85-plus replication study, Danish repli-
cation study, and the meta-analysis. (B) Results of the meta-
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697association analysis with survival into old age of the 58
prioritized SNPs in male cases compared to all controls. (C)
Results of the meta-association analysis with survival into old
age of the 58 prioritized SNPs in female cases compared to all
controls.
Table S3 (A) Results of the prospective analysis of rs2075650
adjusted for rs429358 (e4) and rs7412 (e2). (B) Results of the
prospective analysis of rs429358 (e4).
Table S4 Association of LLS GWAS SNPs selected from the Alz-
Gene database [http://www.alzgene.org/, (Bertram et al.,
2007)] with survival into old age.
Table S5 Association of LLS GWAS SNPs within a 10 Kb window
around FOXO3A and AKT1 with survival into old age.
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